Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.

Sun, Bowen; Jensen, Nathaniel R; Chung, Dongjun; Yang, Meixiang; LaRue, Amanda C; Cheung, Hiu Wing; Wang, Qi

Sun, Bowen; Jensen, Nathaniel R; Chung, Dongjun; Yang, Meixiang; LaRue, Amanda C; Cheung, Hiu Wing; Wang, Qi.

Afiliação

Sun B; The First Affiliate Hospital, Biomedical Translational Research Institute, Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University Guangzhou 510632, China.
Jensen NR; Department of Pathology and Laboratory Medicine, Medical University of South Carolina Charleston, SC 29425, USA.
Chung D; Department of Pathology and Laboratory Medicine, Medical University of South Carolina Charleston, SC 29425, USA.
Yang M; Ralph H. Johnson VAMC, Department of Veterans Affairs Charleston, SC 29401, USA.
LaRue AC; Department of Public Health Sciences, Medical University of South Carolina Charleston, SC 29425, USA.
Cheung HW; The First Affiliate Hospital, Biomedical Translational Research Institute, Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University Guangzhou 510632, China.
Wang Q; Department of Pathology and Laboratory Medicine, Medical University of South Carolina Charleston, SC 29425, USA.

Am J Cancer Res ; 9(1): 145-159, 2019.

Article em En | MEDLINE | ID: mdl-30755818

Palavras-chave

GAB2; High-grade serous ovarian cancer; PI3K; SHP2

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Am J Cancer Res Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google